P4-337: Dimebon improves cognition, function, and behavior in mild and moderate Alzheimer's disease: Results by severity of a one-year, double-blind, placebo-controlled study

2008 ◽  
Vol 4 ◽  
pp. T771-T771
Author(s):  
Rachelle S. Doody ◽  
Svetlana Gavrilova ◽  
Ronald Thomas ◽  
Paul Aisen ◽  
Sergey Bachurin ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
One Year ◽  
And Behavior

scholarly journals Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study

2012 ◽  
Vol 4 (5) ◽  
pp. 43 ◽  
Author(s):  
John M Ringman ◽  
Sally A Frautschy ◽  
Edmond Teng ◽  
Aynun N Begum ◽  
Jenny Bardens ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

DHEA treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled study

Neurology ◽  
2003 ◽  
Vol 60 (7) ◽  
pp. 1071-1076 ◽  
Author(s):  
O.M. Wolkowitz ◽  
J.H. Kramer ◽  
V.I. Reus ◽  
M.M. Costa ◽  
K. Yaffe ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Dhea Treatment

P2-402: Double-blind, placebo-controlled study of three different dosages of cerebrolysin in patients with mild to moderate Alzheimer's disease

2006 ◽  
Vol 2 ◽  
pp. S364-S364 ◽  
Author(s):  
Anton Alvarez ◽  
Marta Laredo ◽  
Miguel Varela ◽  
Ramon Cacabelos ◽  
Carolina Sanpedro ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document